Language:English
Language:

Xcessbio

Place your promotion here

You have no items in your shopping cart.

HCI-2509 (SP2509),  Reversible LSD1 Inhibitor.

HCI-2509 (SP2509), Reversible LSD1 Inhibitor.

$109.00
A highly potent, specific, and reversible Lysine Specific Demethylase-1 (LSD1) inhibitor with in vivo efficacy.
Catalog No. Unit Price Qty
M60160-2s 2 mg solid $109.00
M60160-2 10 mM in DMSO (0.457 mL) $109.00

Details

Product Information
Molecular Weight: 437.90
Formula: C19H20ClN3O5S
Purity: ≥98%
CAS#: 1423715-09-6
Solubility: DMSO up to 50 mM
Chemical Name: (E)-N'-(1-(5-chloro-2-hydroxyphenyl)ethylidene)-3-(morpholinosulfonyl)benzohydrazide
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

Biological Activity:


HCI-2509 (also named as SP2509 or LSD1-C12) is a highly potent, specific, and reversible Lysine Specific Demethylase-1 (LSD1) inhibitor. It inhibits LSD1 in biochemical assay with an IC50 ~13 nM, and has no activity against monoamine oxidase proteins MAO-A and MAO-B (>300 µM). HCI-2509 is a non-competitive inhibitor to bind LSD1, changes its solution dynamics in a manner distinct from TCP. It has minimal inhibition of CYPs and hERG, shows cellular activity against several cancer cell lines including endometrial, breast, colorectal, pancreatic, and prostate cancer (IC50 ~0.3-2.5 µM). HCI-2509 displayed sing-agent efficacy in multiple xenograft models and had good PK/PD relationship by using tumor histone H3K4 and H3K9 methylation. HCI-2509 serves as a very useful chemical probe to study the target biology of LSD1.

How to Use:


In vitro: HCI-2509 was used at 1 µM in vitro.
In vivo: HCI-2509 was administered through IP injection at 25-30 mg/kg once per day in xenografts models.

Reference:

  • 1. Fiskus W, et al. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. (2014) Leukemia. 28(11):2155-64. 
  • 2. Sorna V, et al. High-Throughput Virtual Screening Identifies Novel N'-(1-Phenylethylidene)-benzohydrazides as Potent, Specific, and Reversible LSD1 Inhibitors. (2013) J Med Chem. 56(23):9496-508. 
  • 3. Wiles ET, et al. BCL11B is up-regulated by EWS/FLI and contributes to the transformed phenotype in Ewing sarcoma. (2013) PLoS One. 8(3):e59369. 
  • 4. Bret J. Stephens, et al.: Activity of the LSD1 inhibitor HCI-2509 in ER-negative breast cancer cells. (2012) AACR Chicago. Abstract 1045. Cancer Research: April 15, 2012; Volume 72, Issue 8, Supplement 1.
  • 5. Emily R, et al. Inhibition of LSD1 disrupts global EWS/ETS transcriptional function in Ewing sarcoma. (2014) AACR San Diego. Abstract 3679. 

HCI-2509_spec.pdf      
HCI-2509_MSDS.pdf      


Products are for research use only. Not for human use.

Description

Details

Product Information
Molecular Weight: 437.90
Formula: C19H20ClN3O5S
Purity: ≥98%
CAS#: 1423715-09-6
Solubility: DMSO up to 50 mM
Chemical Name: (E)-N'-(1-(5-chloro-2-hydroxyphenyl)ethylidene)-3-(morpholinosulfonyl)benzohydrazide
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

Biological Activity:


HCI-2509 (also named as SP2509 or LSD1-C12) is a highly potent, specific, and reversible Lysine Specific Demethylase-1 (LSD1) inhibitor. It inhibits LSD1 in biochemical assay with an IC50 ~13 nM, and has no activity against monoamine oxidase proteins MAO-A and MAO-B (>300 µM). HCI-2509 is a non-competitive inhibitor to bind LSD1, changes its solution dynamics in a manner distinct from TCP. It has minimal inhibition of CYPs and hERG, shows cellular activity against several cancer cell lines including endometrial, breast, colorectal, pancreatic, and prostate cancer (IC50 ~0.3-2.5 µM). HCI-2509 displayed sing-agent efficacy in multiple xenograft models and had good PK/PD relationship by using tumor histone H3K4 and H3K9 methylation. HCI-2509 serves as a very useful chemical probe to study the target biology of LSD1.

How to Use:


In vitro: HCI-2509 was used at 1 µM in vitro.
In vivo: HCI-2509 was administered through IP injection at 25-30 mg/kg once per day in xenografts models.

Reference:

  • 1. Fiskus W, et al. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. (2014) Leukemia. 28(11):2155-64. 
  • 2. Sorna V, et al. High-Throughput Virtual Screening Identifies Novel N'-(1-Phenylethylidene)-benzohydrazides as Potent, Specific, and Reversible LSD1 Inhibitors. (2013) J Med Chem. 56(23):9496-508. 
  • 3. Wiles ET, et al. BCL11B is up-regulated by EWS/FLI and contributes to the transformed phenotype in Ewing sarcoma. (2013) PLoS One. 8(3):e59369. 
  • 4. Bret J. Stephens, et al.: Activity of the LSD1 inhibitor HCI-2509 in ER-negative breast cancer cells. (2012) AACR Chicago. Abstract 1045. Cancer Research: April 15, 2012; Volume 72, Issue 8, Supplement 1.
  • 5. Emily R, et al. Inhibition of LSD1 disrupts global EWS/ETS transcriptional function in Ewing sarcoma. (2014) AACR San Diego. Abstract 3679. 

HCI-2509_spec.pdf      
HCI-2509_MSDS.pdf      


Products are for research use only. Not for human use.

Reviews

Write Your Review

How do you rate this product? *

Price:
Value:
Quality: